UroGen Pharma announced final five-year results from the OLYMPUS long-term follow-up study of JELMYTO for low-grade upper tract urothelial cancer (LG-UTUC). Published in Therapeutic Advances in Urology, the results showed durable responses to treatment.
Among patients who initially achieved a complete response, the median response duration was 47.8 months.
Among patients in the long-term follow-up portion of the study, 75% remained event-free as of March 2025. No patients progressed to high-grade disease during the extended follow-up.